Dalkara Deniz, Goureau Olivier, Marazova Katia, Sahel José-Alain
1 Sorbonne Universités, UPMC Université Paris 06, INSERM, CNRS, Institut de la Vision , France .
2 Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts , DHU Sight Restore, INSERM-DHOS CIC 1423, France .
Hum Gene Ther. 2016 Feb;27(2):134-47. doi: 10.1089/hum.2015.147.
Retinal degenerative diseases are a leading cause of irreversible blindness. Retinal cell death is the main cause of vision loss in genetic disorders such as retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis, as well as in complex age-related diseases such as age-related macular degeneration. For these blinding conditions, gene and cell therapy approaches offer therapeutic intervention at various disease stages. The present review outlines advances in therapies for retinal degenerative disease, focusing on the progress and challenges in the development and clinical translation of gene and cell therapies. A significant body of preclinical evidence and initial clinical results pave the way for further development of these cutting edge treatments for patients with retinal degenerative disorders.
Hum Gene Ther. 2016-2
Mol Biotechnol. 2021-9
Stem Cells Transl Med. 2016-2
Hum Gene Ther Clin Dev. 2015-3
Annu Rev Genomics Hum Genet. 2019-4-24
Clin Genet. 2013-5-13
Yale J Biol Med. 2017-12-19
Hum Gene Ther. 2018-7-24
Cell Prolif. 2025-2
Biomolecules. 2024-7-25
Br J Ophthalmol. 2024-3-20
Ther Adv Ophthalmol. 2022-11-4
Ophthalmology. 2016-3
J Clin Invest. 2015-9
J Clin Med. 2014-12-19
Curr Biol. 2015-8-17
Ophthalmology. 2015-8